Market capitalization | $513.64m |
Enterprise Value | $293.18m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
P/B ratio (TTM) P/B ratio | 2.43 |
Revenue (TTM) Revenue | $0.00 |
EBIT (operating result TTM) EBIT | $-65.83m |
Free Cash Flow (TTM) Free Cash Flow | $-43.38m |
Cash position | $226.06m |
As a Free StocksGuide user, you can view scores for all 6,914 stocks worldwide.
7 Analysts have issued a Larimar Therapeutics Inc forecast:
7 Analysts have issued a Larimar Therapeutics Inc forecast:
Jun '24 |
+/-
%
|
||
Revenue | - - |
-
|
|
Gross Profit | -0.32 -0.32 |
52%
52%
|
|
EBITDA | -66 -66 |
82%
82%
|
EBIT (Operating Income) EBIT | -66 -66 |
82%
82%
|
Net Profit | -58 -58 |
79%
79%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases. The company's lead compound, CTI-1601, is being evaluated in a Phase 1 clinical program as a potential treatment for Friedreich's ataxia, a rare and progressive genetic disease. It also focuses on using its intracellular platform to design other fusion proteins to target additional rare diseases characterized by deficiencies in intracellular bioactive compounds. The company is headquartered in Bala Cynwyd, Pennsylvania.
Head office | United States |
CEO | Carole Ben-Maimon |
Employees | 42 |
Founded | 2005 |
Website | larimartx.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.